Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

IkT-001Pro

Other · developed by Inhibikase Therapeutics

Phase 2 Most advanced trial (none active)
IKT Developer
1 Registered trials

What is IkT-001Pro?

IkT-001Pro is an investigational drug studied in Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH).

At a glance

Drug type
Other
Therapy area
Respiratory
Developer
Inhibikase Therapeutics (IKT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
WQJ8L8YJ7U

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06643143 Phase 2 Pulmonary Arterial Hypertension (PAH) Withdrawn IKT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pulmonary Arterial Hypertension (PAH)Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)

More from Inhibikase Therapeutics

IKT-001 Phase 3

Follow IKT, the company behind IkT-001Pro

See IKT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IKT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.